Supplementary Methods from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Stefanie Hammer(Bayer (Norway)), Dominik Mumberg(Bayer (Germany))
Cited by 0
Related Papers
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
|Clinical Cancer Research|2019|121
Isolation of more potent oncolytic paramyxovirus by bioselection
|Gene Therapy|2012|12